Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Status:
Unknown status
Trial end date:
2020-07-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and activity of BPX-701 in participants
with relapsed AML, previously treated MDS, or metastatic uveal melanoma expressing high
levels of PReferentially expressed Antigen in MElanoma (PRAME). Participants' T cells are
modified to recognize and target the PRAME tumor marker on cancer cells.